Lipocine Inc. (NASDAQ:LPCN) has reported EPS of $(0.26) for its last quarter. For the ongoing quarter, market analysts are anticipating EPS to come to $-0.23.
To generate the revenue, Lipocine Inc. recorded direct expenses amounting to $7,093, being the cost of sales. After subtracting the same, the firm closed with gross profit of $(7,093).
Let’s look into the technical of the stock
The Barchart Technical Opinion rating is a 56% Buy with a Strongest short term outlook on maintaining the current direction. Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.
Because, company incurred other costs in the course of its businesses, deducting from the gross profit and dividing the variance by the number of shares due yielded the recorded revenue of $(0.26). Investors should bear in mind that Lipocine Inc. closed the last quarter with diluted shares due amounting to 18.71M.
What is Lipocine Inc.?s liquidity position and can it continue funding its businesses? The firm closed the previous quarter with cash balance of 6.94M%, having posted free cash flow of $(3.14M) during the last quarter. Net cash flow from businesses during the quarter was $(3.14M), resulting in net change in cash of $1.38M.
What about the performance of the firm’s balance sheet? Lipocine Inc. had total assets of $27.22M at the end of the recent quarter, whereas total liabilities amounted to $2.34M.
As for the Wall Street sentiment pertaining the stock, some 4 analysts have remarked on Lipocine Inc. so far, giving it an average recommendation of Buy. Investors should understand that a call of 1 up to 1.24 implies the stock is a BUY, whereas recommendation of 2.75 up to 3.00 implies a stock is a SELL.
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the Company will host a conference call and webcast today, June 19, 2017 at 5:00 p.m. Eastern time to discuss top-line results from its Dosing Validation and Dosing Flexibility studies.